NewMed Energy (NWMD) J.P. Morgan Emerging and Frontier Markets Opportunities Conference presentation summary

Corporate profile

• Tel Aviv-listed TA-35 limited partnership with market capitalization of ~$6.5B and operations spanning the full E&P value chain.

• Portfolio strategy has evolved from domestic operations to regional leadership, alongside global expansion; financial strength is based on cash flow and asset value.

Leviathan asset and commercial position

• 45.34% working interest; 2P reserves of 19.5 tcf and 43 mmbbl condensate, as of Dec. 31, 2025; cumulative production since start-up of 2.2 tcf and 5 mmbbl condensate.

• Production capacity reached 15.8 bcm/y in 2026, with expansion to 21+ bcm/y targeted for 2029; two prospective targets carry 368 mmbboe P50 resources and 18–19% geological success probability.

• Long-term sales include take-or-pay commitments and floor-price protections; contracted volumes rise to 6.7 bcm/y in 2026 and 12.5 bcm/y in 2030, plus interruptible volumes.

• Sales markets include Israel, Jordan and Egypt; the asset is positioned as a supply source for regional demand and Israel’s energy independence.

Regional demand and export infrastructure

• Egyptian gas-market supply deficit is projected to reach 40–50 bcm/y by the end of the decade.

• Israeli domestic demand is projected to increase by 5.3 bcm by 2035, from 13.9 bcm in 2024 to 19.2 bcm.

• Export capacity initiatives include EMG debottlenecking, FAJR compression and the Nitzana pipeline; total expected Leviathan export capacity is 1,625 mmcf/d.